Quick answers

What is PT-141 and what is it used for in research?
PT-141 is classified within the Body Recomposition group. 7-amino-acid melanocortin agonist (bremelanotide). FDA-approved for HSDD in premenopausal women. Research applications focus on the pathways outlined below. All references on this page describe published research only, PT-141 is supplied for in-vitro and laboratory use, not for human consumption.
How does PT-141 work?
Primary mechanism: MC4-receptor agonist; investigated for sexual function. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for PT-141 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical PT-141 research dose?
Published research protocols for PT-141 describe per-dose ranges of 1–1.75 mg PRN, with a weekly total near As needed, administered prn sc. Typical cycle: prn. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy PT-141 in Thailand?
PT-141 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can PT-141 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is PT-141?

PT-141 is a research peptide in the Body Recomposition class. MC4-receptor agonist; investigated for sexual function. It is studied at per-dose ranges of 1–1.75 mg PRN (As needed weekly), administered prn sc over cycles of prn. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

7-amino-acid melanocortin agonist (bremelanotide). FDA-approved for HSDD in premenopausal women.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does PT-141 work?

PT-141 (bremelanotide) is a 7-amino-acid cyclic melanocortin agonist with relative selectivity for the MC4 receptor. Unlike PDE5-inhibitor approaches, bremelanotide acts centrally via MC4R on hypothalamic pathways that modulate sexual arousal. FDA approval (2019) covers hypoactive sexual desire disorder (HSDD) in premenopausal women.

Receptor binding affinity and post-receptor signalling for PT-141 remain areas of active investigation; several proposed effects within the Body Recomposition class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

PT-141 pharmacokinetics

Half-life
Approximately 2 hours after SC administration; clinical formulation is dosed PRN.
Bioavailability
SC bioavailability supports on-demand dosing profile.
Route of administration
Subcutaneous injection PRN, typically 45 minutes before anticipated activity.
Metabolic clearance
Proteolytic clearance; FDA label describes standard renal excretion of metabolites.

PT-141 research timeline

  1. 2019 Kingsberg et al., RECONNECT trials establish efficacy and safety in HSDD (Obstet Gynecol).

PT-141 dosage & protocol

Reference protocol for PT-141 (research context only, drawn from published literature):

  • Per dose: 1–1.75 mg PRN
  • Weekly total: As needed
  • Frequency: PRN SC
  • Cycle: PRN

PT-141 injection & handling

Reconstitution
Clinical product supplied as prefilled autoinjector; research vials reconstituted to label concentration.
Storage
Refrigerated at 2–8 °C; do not freeze.
Sites used in the research literature
Subcutaneous abdomen or thigh, taken at least 45 minutes before anticipated sexual activity per label.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order PT-141
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about PT-141 ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking PT-141

Commonly referenced pairing with PT-141: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a PT-141 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Uncontrolled hypertension. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Compare PT-141 with: Melanotan-II

Citations

  1. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 2019. PMID: 31599840

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.